Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: McNeill, Robert S, Canoutas, Demitra A, Stuhlmiller, Timothy J, Dhruv, Harshil D, Irvin, David M, Bash, Ryan E, Angus, Steven P, Herring, Laura E, Simon, Jeremy M, Skinner, Kasey R, Limas, Juanita C, Chen, Xin, Schmid, Ralf S, Siegel, Marni B, Van Swearingen, Amanda E D, Hadler, Michael J, Sulman, Erik P, Sarkaria, Jann N, Anders, Carey K, Graves, Lee M, Berens, Michael E, Johnson, Gary L, Miller, C Ryan
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737415/
https://ncbi.nlm.nih.gov/pubmed/28379424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados